ED50 and ED95 of remimazolam in combination with propofol for intravenous anaesthesia in hysteroscopy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200058865

Enrollment

Unknown

Registered

2022-04-18

Start date

2022-05-09

Completion date

Unknown

Last updated

2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hysteroscopy

Interventions

1:0.05mg/kg remimazolam

2:0.075mg/kg remimazolam

3:0.1mg/kg remimazolam

4:0.125mg/kg remimazolam

5:0.15mg/kg remimazolam

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1 Patients undergoing hysteroscopy requiring intravenous anaesthesia; 2 ASA 1-2; 3 Age 20-45y; 4 BMI 18-30kg/m2

Exclusion criteria

Exclusion criteria: 1 cardiopulmonary disease; 2 Alcohol abuse, liver and kidney dysfunction; 3 OSAHS; 4 Chronic use of tranquillizers,opioids antidepressants; 5 anesthetic drug allergy; 6 difficulty in cervical dilatation

Design outcomes

Primary

Measure	Time frame
successful rate of cervical dilatation with different doses remimazolam;	—

Secondary

Measure	Time frame
incidence of adverse events;	—

Countries

China

Contacts

Public ContactXiaowei Qian

qianxw@zju.edu.cn15700157161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026